AU2002349352A1 - Keratinocytes which may be used as biologically active substances for the treatment of wounds - Google Patents

Keratinocytes which may be used as biologically active substances for the treatment of wounds

Info

Publication number
AU2002349352A1
AU2002349352A1 AU2002349352A AU2002349352A AU2002349352A1 AU 2002349352 A1 AU2002349352 A1 AU 2002349352A1 AU 2002349352 A AU2002349352 A AU 2002349352A AU 2002349352 A AU2002349352 A AU 2002349352A AU 2002349352 A1 AU2002349352 A1 AU 2002349352A1
Authority
AU
Australia
Prior art keywords
keratinocytes
wounds
treatment
biologically active
active substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2002349352A
Other versions
AU2002349352B2 (en
Inventor
Petra Eberhardt
Wolfgang Noe
Katharina Reif
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10151296A external-priority patent/DE10151296A1/en
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of AU2002349352A1 publication Critical patent/AU2002349352A1/en
Application granted granted Critical
Publication of AU2002349352B2 publication Critical patent/AU2002349352B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2002349352A 2001-10-17 2002-10-14 Keratinocytes which may be used as biologically active substances for the treatment of wounds Ceased AU2002349352B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10151296A DE10151296A1 (en) 2001-10-17 2001-10-17 Keratinocytes useful as a biologically active substance in the treatment of wounds
DE10151296.1 2001-10-17
PCT/EP2002/011459 WO2003033686A2 (en) 2001-10-17 2002-10-14 Keratinocytes which may be used as biologically active substances for the treatment of wounds

Publications (2)

Publication Number Publication Date
AU2002349352A1 true AU2002349352A1 (en) 2003-07-03
AU2002349352B2 AU2002349352B2 (en) 2007-11-01

Family

ID=7702826

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002349352A Ceased AU2002349352B2 (en) 2001-10-17 2002-10-14 Keratinocytes which may be used as biologically active substances for the treatment of wounds

Country Status (30)

Country Link
US (3) US7247478B2 (en)
EP (1) EP1440148B1 (en)
JP (1) JP4476625B2 (en)
KR (1) KR101019916B1 (en)
CN (1) CN100432220C (en)
AR (1) AR036827A1 (en)
AT (1) ATE474039T1 (en)
AU (1) AU2002349352B2 (en)
BR (1) BR0213282A (en)
CA (1) CA2461141C (en)
CO (1) CO5580844A2 (en)
DE (2) DE10151296A1 (en)
DK (1) DK1440148T3 (en)
EA (1) EA009073B1 (en)
EC (1) ECSP045065A (en)
ES (1) ES2345767T3 (en)
HR (1) HRP20040347B1 (en)
HU (1) HU228887B1 (en)
IL (2) IL161442A0 (en)
MX (1) MXPA04003487A (en)
MY (1) MY137828A (en)
NO (1) NO334974B1 (en)
NZ (1) NZ532899A (en)
PE (1) PE20030627A1 (en)
PL (1) PL367338A1 (en)
RS (1) RS30104A (en)
UA (1) UA81398C2 (en)
UY (1) UY27486A1 (en)
WO (1) WO2003033686A2 (en)
ZA (1) ZA200402306B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP2481287B1 (en) 2003-08-01 2016-07-20 Stratatech Corporation Human skin equivalents expressing exogenous polypeptides
WO2006010161A2 (en) * 2004-07-20 2006-01-26 The Regents Of The University Of California In vitro wound healing assay and device
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
AU2008311813B2 (en) * 2007-10-19 2012-01-12 Biointraface, Inc. Novel compositions and related methods, coatings, and articles
PE20091730A1 (en) 2008-04-03 2009-12-10 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
RU2515156C2 (en) 2008-05-27 2014-05-10 Плуристем Лтд. Methods of treating inflammatory diseases of colon
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
BRPI0916997A2 (en) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh DPP-4 INHIBITOR AND ITS USE
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (en) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Saline forms of organic compounds
AR074990A1 (en) 2009-01-07 2011-03-02 Boehringer Ingelheim Int TREATMENT OF DIABETES IN PATIENTS WITH AN INAPPROPRIATE GLUCEMIC CONTROL THROUGH METFORMIN THERAPY
CN107115530A (en) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 Gene diabetes mellitus type utilizes the treatment of DPP IV inhibitor such as BI 1356
KR101927068B1 (en) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 Sequential Combination Therapy by the Weight Reducing Treatment Followed by the DPP-4 Inhibitor
ES2529246T3 (en) * 2010-06-09 2015-02-18 Chanel Parfums Beauté MicroRNA inhibitors for use in the prevention and / or attenuation of skin aging and / or to hydrate the skin
CN102971005A (en) 2010-06-24 2013-03-13 贝林格尔.英格海姆国际有限公司 Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013174769A1 (en) 2012-05-25 2013-11-28 Boehringer Ingelheim International Gmbh Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
JP6615109B2 (en) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Medical use of DPP-4 inhibitors
CN105219697A (en) * 2014-07-04 2016-01-06 赫柏慧康生物科技无锡有限公司 A kind of people's primary keratinocyte is separated the method for preparation
EP3132809A1 (en) 2015-08-21 2017-02-22 Bioskinco GmbH Composition and products comprising senescent cells for use in tissue regeneration
US10668259B2 (en) 2015-10-21 2020-06-02 Materials Science Associates, LLC Metal oxide and polymer controlled delivery systems, sunscreens, treatments, and topical coating applicators
EP3443112B1 (en) * 2016-04-12 2020-08-05 Unicyte EV AG Isolation of extracellular vesicles (evs) from biological fluid samples
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN109055303A (en) * 2018-09-12 2018-12-21 山东麦德克斯生物科技有限公司 A kind of construction method of skin histology
RU2731065C1 (en) * 2019-12-24 2020-08-28 Федеральное государственное бюджетное учреждение науки Институт биологии развития им. Н.К. Кольцова РАН (ИБР РАН) Cryopreservant composition for long-term storage of primary keratinocytes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016038A (en) * 1968-04-01 1977-04-05 Hayashibara Company Process for preparing maltoses from starches
US4016036A (en) 1975-11-14 1977-04-05 Massachusetts Institute Of Technology Process for serially culturing keratinocytes
IT1207525B (en) 1987-06-23 1989-05-25 Ist Naz Ric Sul Cancro METHOD FOR THE PRESERVATION OF TRANSPLANTABLE SHEETS OF EPITELIUM CULTIVATED IN VITRO VITRO.
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
IT1248934B (en) 1990-06-01 1995-02-11 Fidia Spa BIOCOMPATIBLE PERFORATED MEMBRANES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS A SUPPORT FOR THE IN VITRO GROWTH OF EPITHELIAL CELLS, ARTIFICIAL LEATHER THUS OBTAINED AND THEIR USE IN LEATHER TRANSPLANTS
EP0615545B1 (en) 1991-11-20 2000-05-17 N.V. Innogenetics S.A. Lysates derived from keratinocytes for use as wound healing substances
US6585969B1 (en) 1991-11-20 2003-07-01 N. V. Innogenetics S.A. Non-viable keratinocyte cell composition or lysate for promoting wound healing
US5891617A (en) 1993-09-15 1999-04-06 Organogenesis Inc. Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing
US5518878A (en) 1993-09-15 1996-05-21 Organogenesis Inc. Cryopreservation of cultured skin or cornea equivalents with agitation
US5693332C1 (en) 1995-08-11 2001-01-09 Univ California Human keratinocytes supported on a hydrophilic membrane and methods of using same to effect wound closure
AUPP244498A0 (en) 1998-03-18 1998-04-09 Medvet Science Pty. Ltd. Keratinocyte stem cells
DE19917532A1 (en) 1999-04-19 2000-10-26 Christian Toloczyki Carrier-bound keratinocyte stem or precursor cells, useful for cosmetic or therapeutic regeneration of the epidermis

Similar Documents

Publication Publication Date Title
AU2002349352A1 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
IL161442A0 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
AU2002342613A1 (en) Treatment for wounds
EP1425277B8 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
AU2001272849A1 (en) Composition for the treatment of osteoarthritis
AU2000276362A1 (en) Composition for the treatment of diabetes
AU2002213887A1 (en) Process for the antimicrobial treatment of fiber materials
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
AU2002315814A1 (en) Medicinal composition for treatment of interstitial cystitis
AU2002361046A1 (en) Unit for the treatment of histological samples
AU2002322481A1 (en) Use of r-nsaid compounds for anti-hiv treatment
AU2003237969A1 (en) Pharmaceutical composition comprising calcium channel blockers for the treatment of pain
AU1878201A (en) Composition for the treatment of damaged tissue
AU2002327440A1 (en) Treatment of type i diabetes
AU2003263332A1 (en) Wound dressings for the treatment of wound infection
AU2003292882A1 (en) Thrombin from venom of agkistrodon acutus used as drugs for the treatment of haemorrhage
GB0020588D0 (en) Treatment of wounds
AU2683500A (en) Compositions for the treatment of pain
AUPR637001A0 (en) Pharmaceutical composition for the treatment of skin conditions
AUPQ902000A0 (en) Pharmaceutical composition for the treatment of skin conditions
AU2002320937A1 (en) Pharmaceutical preparation for treating wounds
AU2002327697A1 (en) Compounds for the treatment of pain
AU2002237585A1 (en) Method for the treatment of active sludges
AU7445601A (en) Pharmaceutical composition for the treatment of multiple sclerosis
AU2002325743A1 (en) Biofermentor for the treatment of biologically convertible matter